References
- 1. Melton LJ III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002; 17(Suppl 2):N12eN17.
- 2. Bilezikian JP, Cusano NE, Khan AA et al. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016; 2: 16033.
- 3. Yeh MW, Ituart PHG. Incidence and Prevalence of Primary Hyperparathyroidism in a Racially Mixed Population. J Clin Endocrinol Metab 2013;98(3):1122-9.
- 4. Press DM, Siperstein AE, Berber E et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery. 2013 Dec;154(6):1232-7.
- 5. Berger C, Almohareb O, Langsetmo L et al. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf) 2015 Mar;82(3):359-68.
- 6. Abood A, Vestergaard P. Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013; 60:A4567.
- 7. Eufrazino C, Veras A, Bandeira F. Epidemiology of primary hyperparathyroidism and its no n-classical manifestations in the city of Recife, Brazil. Clin Med Insights Endocrinol Diabetes 2013; 6:69–74.
- 8. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145–58.
- 9. Cope O. The Story of Hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966 274(21), 1174-1182.
- 10. Shinkov A, Borissova AM, Kovatcheva R et al. Comparison of thyroid nodule prevalence in two populationbased studies in Bulgaria: 2006 and 2012. Endocrine Abstracts 2016;41:EP1039.
- 11. Borissova AM, Vlahov JD, Krivoshiev SG et al. The prevalence of hyperparathyroidism in Bulgarian population – analysis of an epidemiological study by the Bulgarian Society of Endocrinology (BSE) – 2012. Endocrinologia 2019;24(4): 207-212.